A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis

Hirschfield et al. (Wed,) studied this question.

www.synapsesocial.com/papers/68e78323b6db6435876f5d7e — DOI: https://doi.org/10.1056/nejmoa2312100

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis· 2022 · 78 citations
2. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis· 2023 · 242 citations
3. Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance· 2008 · 825 citations
4. The 5-D itch scale: a new measure of pruritus· 2009 · 518 citations
5. Diagnostic Accuracy of FibroScan and Factors Affecting Measurements· 2020 · 117 citations